61/8017/2026 - Authorization for Exceptional Use of a Medicine

This tender, identified by reference number 61/8017/2026, relates to the process of obtaining authorization for the exceptional use of a specific medicine. This typically occurs when a particular drug is not widely approved or available for a specific indication or patient population within the country, but there is a compelling medical need. The objective is to establish a procedure or framework for evaluating and granting such exceptional authorizations. This might involve a review of clinical data, justification from healthcare professionals, and assessment of risks versus benefits. The tender could be for services to support this evaluation process, or it could be a call for pharmaceutical companies to submit applications for exceptional use authorization for their products. Ensuring patient access to potentially life-saving or essential treatments under specific circumstances is the core purpose of this process.

This is a supplies contract in the health and medical services, information and communication technology and Monitoring Evaluation sectors, with a focus on Pharmaceuticals. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 4,762.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.